<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00878228</url>
  </required_header>
  <id_info>
    <org_study_id>29015</org_study_id>
    <nct_id>NCT00878228</nct_id>
  </id_info>
  <brief_title>Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy</brief_title>
  <acronym>PDNV</acronym>
  <official_title>Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting After Hip Arthroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital for Special Surgery, New York</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital for Special Surgery, New York</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a randomized placebo controlled trial to determine whether repeated
      postoperative prophylactic ondansetron (&quot;Zofran&quot;) administration will prevent postoperative
      and/or postdischarge nausea and vomiting in patients undergoing ambulatory hip arthroscopy.
      Ondansetron will be administered in the intra- and post-operative period. These individuals
      will be followed on postoperative days 1, 2, and 3. It is hypothesized that the incidence of
      postdischarge nausea and vomiting (PDNV) will be significantly decreased by postoperative
      prophylactic administration of multiple doses of ondansetron (Zofran).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Nausea</measure>
    <time_frame>Postdischarge Day 1</time_frame>
    <description>Percentage of participants with nausea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of Nausea</measure>
    <time_frame>Postdischarge Day 1</time_frame>
    <description>Percentage of participants reporting moderate or severe nausea in the first 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Nausea and Vomiting on Quality of Life</measure>
    <time_frame>Postdischarge Day 1</time_frame>
    <description>Percentage of participants whose quality of life was impacted by nausea and vomiting</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Nausea and Vomiting, Postoperative</condition>
  <arm_group>
    <arm_group_label>Study Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study group will receive intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron</intervention_name>
    <description>The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.</description>
    <arm_group_label>Study Group</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients of Dr. Coleman or Dr. Kelly ages 18 to 65 undergoing arthroscopic hip
             surgery

          -  Planned use of neuraxial anesthesia

          -  Ability to follow study protocol

          -  Willing to complete daily diary and be interviewed daily for three days after
             discharge

        Exclusion Criteria:

          -  Patients younger than 18 years old and older than 65

          -  Patients unable to undergo a spinal or epidural anesthetic

          -  Having nausea or vomiting within 24 hours of the surgery

          -  Receiving drugs with anti-emetic properties within 24 hours of the surgery (e.g
             Zofran, Compazine, Phenergan, Reglan)

          -  Chronic opioid use (defined as daily or almost daily use of opioids for &gt;3 months)

          -  Hypersensitivity and/or allergy to ondansetron

          -  Intraoperative use of any volatile anesthetic

          -  Contraindication to a short course of NSAIDs (renal failure, intolerance)

          -  Allergy or intolerance to Vicodin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques YaDeau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hosptial for Special Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.hss.edu</url>
    <description>This is the link to the Hospital for Special Surgery home website.</description>
  </link>
  <reference>
    <citation>Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J. Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer. 1997 Jul;5(4):307-13.</citation>
    <PMID>9257427</PMID>
  </reference>
  <reference>
    <citation>Pan PH, Lee SC, Harris LC. Antiemetic prophylaxis for postdischarge nausea and vomiting and impact on functional quality of living during recovery in patients with high emetic risks: a prospective, randomized, double-blind comparison of two prophylactic antiemetic regimens. Anesth Analg. 2008 Aug;107(2):429-38. doi: 10.1213/ane.0b013e318172f992.</citation>
    <PMID>18633020</PMID>
  </reference>
  <reference>
    <citation>Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, Hooper VD, Kovac AL, Kranke P, Myles P, Philip BK, Samsa G, Sessler DI, Temo J, Tram√®r MR, Vander Kolk C, Watcha M; Society for Ambulatory Anesthesia. Society for Ambulatory Anesthesia guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2007 Dec;105(6):1615-28, table of contents.</citation>
    <PMID>18042859</PMID>
  </reference>
  <reference>
    <citation>Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, Zernak C, Danner K, Jokela R, Pocock SJ, Trenkler S, Kredel M, Biedler A, Sessler DI, Roewer N; IMPACT Investigators. A factorial trial of six interventions for the prevention of postoperative nausea and vomiting. N Engl J Med. 2004 Jun 10;350(24):2441-51.</citation>
    <PMID>15190136</PMID>
  </reference>
  <reference>
    <citation>White PF, O'Hara JF, Roberson CR, Wender RH, Candiotti KA; POST-OP Study Group. The impact of current antiemetic practices on patient outcomes: a prospective study on high-risk patients. Anesth Analg. 2008 Aug;107(2):452-8. doi: 10.1213/ane.0b013e31817b842c.</citation>
    <PMID>18633023</PMID>
  </reference>
  <reference>
    <citation>White PF, Sacan O, Nuangchamnong N, Sun T, Eng MR. The relationship between patient risk factors and early versus late postoperative emetic symptoms. Anesth Analg. 2008 Aug;107(2):459-63. doi: 10.1213/ane.0b013e31817aa6e4.</citation>
    <PMID>18633024</PMID>
  </reference>
  <reference>
    <citation>Pavlin DJ, Chen C, Penaloza DA, Polissar NL, Buckley FP. Pain as a factor complicating recovery and discharge after ambulatory surgery. Anesth Analg. 2002 Sep;95(3):627-34, table of contents.</citation>
    <PMID>12198050</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2009</study_first_submitted>
  <study_first_submitted_qc>April 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 8, 2009</study_first_posted>
  <results_first_submitted>July 23, 2012</results_first_submitted>
  <results_first_submitted_qc>July 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2012</results_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nausea</mesh_term>
    <mesh_term>Vomiting</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Group</title>
          <description>The study group received intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>The control group received IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Group</title>
          <description>The study group received intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>The control group received IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="37"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>98 patients were enrolled in the study, but 22 were excluded for various reasons. The remaining 76 patients were analyzed for the study.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="14"/>
                    <measurement group_id="B2" value="37" spread="11"/>
                    <measurement group_id="B3" value="39" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>98 patients were enrolled in the study, but 22 were excluded for various reasons. The remaining 76 patients were analyzed for the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Nausea</title>
        <description>Percentage of participants with nausea</description>
        <time_frame>Postdischarge Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>The study group received intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group received IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Nausea</title>
          <description>Percentage of participants with nausea</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Nausea</title>
        <description>Percentage of participants reporting moderate or severe nausea in the first 24 hours</description>
        <time_frame>Postdischarge Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>The study group received intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group received IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Nausea</title>
          <description>Percentage of participants reporting moderate or severe nausea in the first 24 hours</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Nausea and Vomiting on Quality of Life</title>
        <description>Percentage of participants whose quality of life was impacted by nausea and vomiting</description>
        <time_frame>Postdischarge Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Group</title>
            <description>The study group received intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The control group received IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).</description>
          </group>
        </group_list>
        <measure>
          <title>Impact of Nausea and Vomiting on Quality of Life</title>
          <description>Percentage of participants whose quality of life was impacted by nausea and vomiting</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Study Group</title>
          <description>The study group received intraoperative IV ondansetron and also postoperative oral ondansetron tablets (8 mg each day for two days).</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>The control group received IV ondansetron intraoperatively and then oral placebo tablets (for 2 days).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Kim</name_or_title>
      <organization>Hospital for Special Surgery</organization>
      <phone>212-606-1206</phone>
      <email>KimD@hss.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

